Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
William Tamborlane
Yale University, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novo Nordisk Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
This SFI is valued in the range of (b)(4).
Yale initially reported this FCOI on 12/18/12 under year 07 of this award (via a FCOI 1995 Report). On 1/3/13, Ms. Shannon Oden requested that Yale provide the nature of the conflict and describe how the FCOI was managed. On 1/17/13, Yale resubmitted the 1995 FCOI Report to include an attachment describing the nature and value of the SFI, the nature of the conflict and how the conflict was managed.
I am now submitting this 2011 Regulation FCOI Report so that Yale can provide Annual Reports with respect to this FCOI/entity.
Yale University Clinical and Translational Science Award Program
(provided by applicant): This research has direct relevance to public health in that its goals are to facilitate clinical research, including by training the next generation of clinical researchers that will lead to better treatments for human disease and better health outcomes.
Filed on March 25, 2014.
Tell us what you know about William Tamborlane's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “William Tamborlane”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| William Tamborlane | Yale University | Conflict of Interest | Takeda Pharmaceuticals | $5,000 - $9,999 |
| William Tamborlane | Yale University | Conflict of Interest | Patton Medical Devices | Value cannot be readily determined |
| William Tamborlane | Yale University | Conflict of Interest | Grove Instruments | Value cannot be readily determined |
| William Tamborlane | Yale University | Conflict of Interest | Grove Instruments | $20,000 - $39,999 |
| William Tamborlane | Yale University | Conflict of Interest | Bristol-Myers Squibb | $20,000 - $39,999 |
| William Tamborlane | Yale University | Conflict of Interest | Insuline Medical, Ltd. | $40,000 - $59,999 |
| William Tamborlane | Yale University | Conflict of Interest | Sanofi US | $5,000 - $9,999 |
| William Tamborlane | Yale University | Conflict of Interest | Boehringer-Ingelheim | $5,000 - $9,999 |
| William Tamborlane | Yale University | Conflict of Interest | Insuline Medical, Ltd. | $20,000 - $39,999 |
| William Tamborlane | Yale University | Conflict of Interest | Novo Nordisk Pharmaceuticals | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.